Dispatch Biotherapeutics
1 known investors
Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
Founders & leadership
LJ
Lex JohnsonCo-Founder and Chief Platform Officer
RL
Ray LiuCo-founder and Head of Synthetic Biology
SO
Sabah OneyChief Executive Officer
Investors · 1
In the news
- The story behind Dispatch Biotherapeutics, an immunotherapy start-up with Penn rootsinquirer.com · 2025
- Facebook cofounder backs cancer start-up that aims to treat all solid tumorscen.acs.org · 2025
- Greater Philadelphia Raises $2.4 Billion Across 403 VC Deals in 2023 | Select Greater Philadelphiaselectgreaterphl.com · 2024